---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001437"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T23:02:53.629442+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%

## Summary
- Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).
- Commercial Channel revenue up 25% in Q4 ($10.9M) and 17% for full year ($42.1M).
- Net loss from continuing ops: Q4 ($2.5M), ($0.17)/share; FY ($8.8M), ($0.60)/share.
- FY 2025 guidance: Commercial Channel $47-49.5M (+12-18%), OEM Channel $64-68.5M (-12-18%).
- Sale of Parcus Medical completed Mar 7; $5.6M in stock repurchased in Q4, $15M plan completed.

## SEC filing metadata
- accession: 0001171843-25-001437
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184325001437/0001171843-25-001437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184325001437/f8k_031225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001437
- JSON: https://secwatch.observer/filing/0001171843-25-001437.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.